In a recent study, we demonstrated that CSs generated from HCFs and HCAECs and treated with plasma from women with early-onset preeclampsia (EOPE; diagnosed before 34 weeks of gestation) or late-onset preeclampsia (LOPE; diagnosed from 34 weeks of gestation) can be used to study changes in angiogenesis, such as the increase in an anti-angiogenic protein, FKBPL, in the context of LOPE [20]. Here, FKBPL is linked to preeclampsia.